A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

StatusRecruiting
PhasePhase 2/3
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 223 → 230 locations
  2. Primary endpoints: details revised at 1 of 2 entries Show 6 more changesShow less
    • Trial sites expanded: 220 → 223 locations
    • Primary completion date: Jan 17, 2028 to Jan 23, 2028
    • Study completion date: Dec 10, 2029 to Dec 24, 2029
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 2 of 21 entries
    • Study description expanded, about 8 words
  3. Trial sites expanded: 214 → 220 locationsv29
  4. Trial sites expanded: 211 → 214 locationsv28
  5. Trial sites expanded: 205 → 211 locationsv27
  6. Trial sites expanded: 188 → 205 locationsv26
  7. Trial sites expanded: 180 → 188 locationsv25
  8. Trial sites expanded: 153 → 180 locationsv24
  9. Trial sites expanded: 135 → 153 locationsv23
  10. Trial sites expanded: 129 → 135 locationsv22
  11. Trial sites expanded: 125 → 129 locationsv21
  12. Trial sites expanded: 114 → 125 locationsv20
  13. Trial sites expanded: 101 → 114 locationsv19
  14. Trial sites expanded: 98 → 101 locationsv18
  15. Trial sites expanded: 91 → 98 locationsv17
  16. Study sites: 68 to 91v16
  17. Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (21)
    v15
  18. Study sites: 64 to 68
    • Primary completion date: Jan 30, 2028 to Jan 17, 2028
    • Study completion date: Dec 23, 2029 to Dec 10, 2029
    v14
  19. Study sites: 50 to 64v13
  20. Study sites: 33 to 50v12
  21. Study sites: 22 to 33v11
  22. Study sites: 12 to 22v10
  23. Study sites: 9 to 12v9
  24. Trial status: Not Yet Recruiting to Recruitingv8 Show 4 more changesShow less
    • Start date: Aug 29, 2025 to Oct 3, 2025
    • Study sites: 0 to 9
    • Primary completion date: Dec 13, 2027 to Jan 30, 2028
    • Study completion date: Nov 5, 2029 to Dec 23, 2029
  25. Primary completion date: Feb 7, 2028 to Dec 13, 2027
    • Study completion date: Jan 8, 2030 to Nov 5, 2029
    v7
  26. Eligibility criteria expanded, about 23 words
    • Study description expanded, about 36 words
    v6
  27. Primary completion date: Feb 6, 2028 to Feb 7, 2028
    • Study completion date: Jan 7, 2030 to Jan 8, 2030
    v5
  28. 2 versions Re-verified since Jun 26, 2025, no change to tracked fieldsv3-v4
  29. Primary completion date: Jan 7, 2029 to Feb 6, 2028
    • Study completion date: Jan 7, 2029 to Jan 7, 2030
    v2
  30. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Pancreatic Cancer
1,740 trials monitored
See 105 trials at risk
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Trial Details
NCT Number NCT06989437
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Related terms Anorexia, Cachexia, Fatigue, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Weight Loss
Enrollment 982 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov